SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Talon Therapeutics, Inc. Announces Enrollment and Dosing of the First Patient in the Phase 3 Confirmatory Study of Marqibo(R) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia (HALLMARQ Study)